The new system includes novel Single-Cell Automated Identification (SCAI) technology for AI-powered rapid single-cell verification and documented monoclonality reporting
OXFORD, UK, November 05, 2024 / Biotech Newswire / -- iotaSciences, the Oxford-based leader in single-cell biology handling solutions, announced today the upcoming launch of its newly developed Single-Cell Cloning Platform XT at the Cell 2024 event in London (UK) from November 6-8, 2024.
The Single-Cell Cloning Platform XT is a next-generation instrument based on the existing Single-Cell Cloning Platform and iotaSciences’ proprietary fluid-shaping technology. This upgraded platform offers enhanced automation, from single-cell isolation and culture within miniature cell chambers to the automated transfer of verified monoclonal cultures into 96-well plates to increase overall throughput and speed. It also makes use of the newly developed SCAI technology for integrated Single-Cell Automated Identification and provides a documented monoclonality report.
The Cloning Platform XT builds on the successful use of the first-generation instrument by cell biology & gene therapy researchers worldwide, with a particular focus on stem cell handling and gene editing. Given its additional features, the new platform is now also suitable for cell line development and reporter cell line generation work.
iotaSciences’ Chief Product Officer, Dr Alexander Feuerborn, said: “We are highly excited about the availability of our new Single-Cell Cloning Platform XT, which addresses our customers’ need to receive a full plate of verified monoclonal cultures with reliable, high-quality, results in a documented manner. In addition, we are very proud to debut our newly developed SCAI technology in this next-generation single-cell handling solution.”
“This product advancement is further proof of our strategy to position iotaSciences as a leader in the rapidly evolving field of single-cell biology handling by bringing pioneering novel solutions to this space”, Dr Michael Lutz, CEO at iotaSciences, commented. “Such solutions are key to R&D workflows related to Cell and Gene Therapy (CGT) and other applications, and represent a multimillion-dollar market potential in the coming years.”
About iotaSciences
iotaSciences is a spin-out from the University of Oxford (UK), founded in 2016 by scientists from the Department of Engineering Science and the Sir William Dunn School of Pathology. Since its inception, iotaSciences has been committed to offer researchers highly user-friendly, reliable, and powerful single-cell handling technologies and solutions with unique capabilities that greatly simplify and facilitate breakthrough advances in cell biology and gene therapy.
Contact
iotaSciences Ltd.
Dr Michael Lutz, Chief Executive Officer
+44 (1865) 309630
This email address is being protected from spambots. You need JavaScript enabled to view it.
Keywords: Cloning, Molecular; Cell Biology; Genetic Therapy; Single-Cell Analysis; Cell Separation; Cell Engineering; Clone Cells; Gene Editing; Automation; Technology; Cell Line; Stem Cells; Artificial Intelligence; Research; United Kingdom; iotaSciences; Single-Cell Cloning Platform XT; single-cell biology; gene therapy; Single-Cell Automated Identification (SCAI) technology; AI-powered verification; monoclonality reporting; fluid-shaping technology; automation; gene therapy applications; cell line development; reporter cell line generation; stem cell handling; gene editing; Cell and Gene Therapy (CGT); Dr. Alexander Feuerborn; Dr. Michael Lutz; monoclonal cultures
Source: Biotech Newswire